Dr. Arie Weinstock Leads Medical Marijuana Studies in EpilepsyPosted: February 3, 2016
Arie Weinstock, MD, Professor of Neurology and Division Chief of Child Neurology at Univ. at Buffalo Jacobs School of Medicine and Biomedical Sciences, is conducting medical marijuana studies in refractory forms of epilepsy. The two studies are being supported by GW Pharma, a British pharmaceutical company that manufactures Epidiolex, which consists mostly of cannabidiol, one of the main, non-psychogenic components of marijuana. New York State is also providing the agent through its compassionate use program to 100 children and young adults with treatment-resistant seizures. Twenty of them will be followed through UBMD Neurology and Women and Children’s Hospital of Buffalo. Earlier studies have suggested that cannabidiol added to other regimens is safe and effective in reducing seizures in this population. However, these have been open label studies, and the current clinical trials are more rigorous, using the randomized, double-blinded, placebo-controlled methodology required for registration with the FDA. For more information see http://www.kaleidahealth.org/kyi/news/?i=6811.